S2k-Leitlinie zur Diagnostik und Therapie von Patienten mit Asthma – Addendum 2020

Zusammenfassung

Das vorliegende Addendum zur Leitlinie zur Diagnostik und Therapie von Patienten mit Asthma (2017) ergänzt wichtige neue Erkenntnisse zur Diagnostik und Therapie von Asthma sowie zu neu für die Therapie des Asthmas zugelassenen Medikamenten. Es werden sowohl für Kinder und Jugendliche als auch für Erwachsene mit Asthma die aktuellen, Evidenz-basierten diagnostischen und therapeutischen Empfehlungen dargelegt.

Abstract

The present addendum of the guideline for the diagnosis and treatment of asthma (2017) complements new insights into the diagnosis and management of asthma as well as for the newly approved drugs for the treatment of asthma. Current, evidence-based recommendations on diagnostic and therapeutic approaches are presented for children and adolescents as well as for adults with asthma.

Publikationsverlauf

Artikel online veröffentlicht:
16. März 2021

• Neue Literatur

• 1 Lommatzsch M. Immune Modulation in Asthma: Current Concepts and Future Strategies. Respiration 2020; 99: 566-576
• 2 Robinson D, Humbert M, Buhl R. et al. Revisiting Type 2-high and Type 2-low airway inflammation in asthma: current knowledge and therapeutic implications. Clin Exp Allergy 2017; 47: 161-175
• 3 Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. 2020 Update (Verfügbar unter): www.ginasthma.org
• 4 Global Initiative for Asthma (GINA). Difficult-to-treat and severe asthma in adolescents and adult patients: diagnosis and management. 2020 Update (Verfügbar unter): www.ginasthma.org
• 5 Lommatzsch M, Klein M, Stoll P. et al. Impact of an increase in the inhaled corticosteroid dose on blood eosinophils in asthma. Thorax 2019; 74: 417-418
• 6 Nwaru BI, Ekström M, Hasvold P. et al. Overuse of short-acting β(2)-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme. Eur Respir J 2020; 55: 1901872
• 7 OʼByrne PM, FitzGerald JM, Bateman ED. et al. Inhaled Combined Budesonide-Formoterol as Needed in Mild Asthma. N Engl J Med 2018; 378: 1865-1876
• 8 Bateman ED, Reddel HK, OʼByrne PM. et al. As-Needed Budesonide-Formoterol versus Maintenance Budesonide in Mild Asthma. N Engl J Med 2018; 378: 1877-1887
• 9 Beasley R, Holliday M, Reddel HK. et al. Controlled Trial of Budesonide-Formoterol as Needed for Mild Asthma. N Engl J Med 2019; 380: 2020-2030
• 10 Hardy J, Baggott C, Fingleton J. et al. Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial. Lancet 2019; 394: 919-928
• 11 Reddel HK, FitzGerald JM, Bateman ED. et al. GINA 2019: a fundamental change in asthma management: Treatment of asthma with short-acting bronchodilators alone is no longer recommended for adults and adolescents. Eur Respir J 2019; 53: 1901046
• 12 Reddel HK, Busse WW, Pedersen S. et al. Should recommendations about starting inhaled corticosteroid treatment for mild asthma be based on symptom frequency: a post-hoc efficacy analysis of the START study. Lancet 2017; 389: 157-166
• 13 Sobieraj DM, Weeda ER, Nguyen E. et al. Association of Inhaled Corticosteroids and Long-Acting beta-Agonists as Controller and Quick Relief Therapy With Exacerbations and Symptom Control in Persistent Asthma: A Systematic Review and Meta-analysis. JAMA 2018; 319: 1485-1496
• 14 Buhl R, Tanase AM, Hosoe M. et al. A randomized, double-blind study to compare the efficacy and safety of two doses of mometasone furoate delivered via Breezhaler^® or Twisthaler^® in patients with asthma. Pulm Pharmacol Ther 2020; 62: 101919
• 15 Kornmann O, Mucsi J, Kolosa N. et al. Efficacy and safety of inhaled once-daily low-dose indacaterol acetate/mometasone furoate in patients with inadequately controlled asthma: Phase III randomised QUARTZ study findings. Respir Med 2020; 161: 105809
• 16 van Zyl-Smit RN, Krüll M, Gessner C. et al. Once-daily mometasone plus indacaterol versus mometasone or twice-daily fluticasone plus salmeterol in patients with inadequately controlled asthma (PALLADIUM): a randomised, double-blind, triple-dummy, controlled phase 3 study. The Lancet Respiratory Medicine; 2020 DOI: 10.1016/S2213-2600(20)30178-8
• 17 Kerstjens HAM, Maspero J, Chapman KR. et al. Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study. The Lancet Respiratory Medicine; 2020 DOI: 10.1016/S2213-2600(20)30190-9
• 18 Watz H, Hohlfeld JM, Singh D. et al. Letter to the editor: indacaterol/glycopyrronium/mometasone furoate compared with salmeterol/fluticasone propionate in patients with asthma: a randomized controlled cross-over study. Respir Res 2020; 21: 87
• 19 Gessner C, Kornmann O, Maspero J. et al. Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: A randomised, Phase IIIb, non-inferiority study (ARGON). Respiratory Medicine 2020; 170: 106021 DOI: 10.1016/j.rmed.2020.106021.
• 20 Virchow JC, Kuna P, Paggiaro P. et al. Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials. Lancet 2019; 394: 1737-1749
• 21 Lee LA, Bailes Z, Barnes N. et al. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. Lancet Respir Med; 2021 9. 69-84
• 22 Bleecker ER, FitzGerald JM, Chanez P. et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet 2016; 388: 2115-2117
• 23 FitzGerald JM, Bleecker ER, Nair P. et al. Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2016; 388: 2128-2141
• 24 Nair P, Wenzel S, Rabe KF. et al. Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma. N Engl J Med 2017; 376: 2448-2458
• 25 Israel E, Reddel HK. Severe and Difficult-to-Treat Asthma in Adults. N Engl J Med 2017; 377: 965-76
• 26 Castro M, Corren J, Pavord ID. et al. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. N Engl J Med 2018; 378: 2486-2496
• 27 Rabe KF, Nair P, Brusselle G. et al. Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma. N Engl J Med 2018; 378: 2475-2485
• 28 Bachert C, Han JK, Desrosiers M. et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet 2019; 394: 1638-1650
• 29 Blauvelt A, de Bruin-Weller M, Gooderham M. et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 2017; 389: 2287-2303
• 30 Rodrigo GJ, Neffen H. Systematic review on the use of omalizumab for the treatment of asthmatic children and adolescents. Pediatr Allergy Immunol 2015; 26: 551-556
• 31 Gevaert P, Omachi TA, Corren J. et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol 2020; 146: 595-605